Show simple item record

dc.contributor.authorM. El-Deeb, Ibrahimen_US
dc.contributor.authorM. Bayoumi, Saiden_US
dc.contributor.authorA. El-Sherbeny, Magdaen_US
dc.contributor.authorA.-M. Abdel-Aziz, Alaaen_US
dc.date.accessioned2017-05-03T15:59:05Z
dc.date.available2017-05-03T15:59:05Z
dc.date.issued2010en_US
dc.date.modified2011-07-20T07:06:41Z
dc.identifier.issn02235234en_US
dc.identifier.doi10.1016/j.ejmech.2010.02.038en_AU
dc.identifier.urihttp://hdl.handle.net/10072/37838
dc.description.abstractNovel derivatives of 5-(substituted)benzylidene-3-(4-substituted)phenylsulfonylimidazolidine-2,4-diones (3a-r), 1-(4-substituted)phenylsulfonyl-3-(4-substituted)phenylpyrimidine-2,4,6-(1H,3H,5H)-triones (6a-l), and 3-(4-substituted)phenyl-1-(4-substituted)phenylsulfonylquinazoline-2,4(1H,3H)- diones (8a-l) have been synthesized and tested for their antitumor activity against 60 tumor cell lines taken from 9 different organs. The tested compounds have showed good inhibitory effect at the ovarian cancer (IGROV1) cell line. A significant inhibition for (RXF393) renal cancer cells was observed with series 3 compounds, while in the other two series 6 and 8, there was a significant inhibition of ovarian cancer cells (OVCAR-8) and melanoma cells (SK-MEL-2). Interestingly; beside the strong inhibition of compound 3q to IGROV1 and RXF393 cells, a great inhibition (199.62%) for (M14) Melanoma cells was observed at the tested concentration (10 卩. ADME-T and pharmacophore prediction methodology were used to study the antitumor activity of the most active compounds and to identify the structural features required for antitumor activity.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_AU
dc.format.extent811332 bytes
dc.format.mimetypeapplication/pdf
dc.languageEnglishen_US
dc.language.isoen_AU
dc.publisherElsevier Franceen_US
dc.publisher.placeFranceen_US
dc.relation.ispartofstudentpublicationNen_AU
dc.relation.ispartofpagefrom2516en_US
dc.relation.ispartofpageto2530en_US
dc.relation.ispartofissue6en_US
dc.relation.ispartofjournalEuropean Journal of Medicinal Chemistryen_US
dc.relation.ispartofvolume45en_US
dc.rights.retentionYen_AU
dc.subject.fieldofresearchBiologically Active Moleculesen_US
dc.subject.fieldofresearchcode030401en_US
dc.titleSynthesis and Antitumor Evaluation of Novel Cyclic Arylsulfonylureas: ADME-T and Pharmacophore Predictionen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.rights.copyrightCopyright 2010 Elsevier Inc. This is the author-manuscript version of this paper. Reproduced in accordance with the copyright policy of the publisher. Please refer to the journal's website for access to the definitive, published version.en_AU
gro.date.issued2010
gro.hasfulltextFull Text


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record